Titan Laboratories Private Limited

Titan Laboratories Private Limited, incorporated on June 14, 2004, is a private pharmaceutical company based in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24100MH2004PTC146928. Its authorized capital is ₹200 lakhs, with a paid-up capital of ₹196.81 lakhs, reflecting a paid-up capital percentage of 98.405%. The registered office is located at A/01-GF & A/101, Plot No. 120, Anand Bhavan, Spectrum Building, R B Mehta Marg, Tilak Road, Ghatkopar East, Mumbai City, Maharashtra 400077, India. The company specializes in the manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

Titan Laboratories Private Limited operates manufacturing facilities in Mumbai, Maharashtra. While specific details regarding plant capacities and specializations are not publicly disclosed, the company's product portfolio indicates a focus on finished pharmaceutical formulations. The manufacturing processes adhere to industry standards to ensure the production of high-quality pharmaceutical products.

The company's leadership comprises directors Piyush Bhailal Shah and Deepak Bhailal Shah. Specific roles and responsibilities of these directors are not publicly detailed. The company's governance structure is designed to oversee operations and strategic direction effectively.

Titan Laboratories Private Limited's export data indicates a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has engaged in 77 shipments across six products in five therapeutic categories, with a total export value of $2.5 million USD. Notably, the top five products include Raltegravir, Exemestane, Nitrofurantoin, Melatonin, and Minocycline, collectively accounting for 95.8% of the export value. However, specific regulatory approvals or market access statuses in these regions are not publicly disclosed.

Titan Laboratories Private Limited's export data does not provide specific information regarding its penetration into emerging markets such as Africa, Latin America, and Southeast Asia. The company's export activities are primarily focused on regulated markets, with no explicit mention of WHO prequalification or similar certifications that would facilitate access to these emerging markets.

The company's export activities are concentrated in regulated markets, with a significant focus on the United States, European Union, United Kingdom, Australia, and Japan. This concentration suggests a strategic emphasis on markets with established regulatory frameworks and demand for pharmaceutical products. While this approach may reduce exposure to emerging market risks, it also indicates a potential opportunity for geographic diversification to mitigate market-specific challenges.

Specific details regarding Titan Laboratories Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide insights into its standing with the U.S. Food and Drug Administration (FDA). This lack of publicly accessible information makes it challenging to assess the company's compliance and standing within the U.S. regulatory framework.

There is no publicly available information regarding Titan Laboratories Private Limited's World Health Organization (WHO) prequalification status or European Union Good Manufacturing Practice (EU GMP) certifications. The company's export data does not indicate any certifications that would facilitate access to international markets requiring such standards. This absence suggests that the company may not currently hold these certifications, which are often essential for global market access.

Titan Laboratories Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its compliance with Indian regulatory requirements for export activities.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Titan Laboratories Private Limited. The company's export data does not indicate any regulatory actions or compliance issues in the markets it serves. This absence suggests that the company maintains a clean regulatory record in its export activities.

Titan Laboratories Private Limited operates in a competitive pharmaceutical industry, exporting products across various therapeutic categories. While specific competitors in overlapping categories are not identified, the company's export data indicates a focus on products such as Raltegravir, Exemestane, Nitrofurantoin, Melatonin, and Minocycline. The market shares of these products range from 0.7% to 16.3%, suggesting a presence in competitive segments. A detailed market share comparison and head-to-head analysis would require access to comprehensive industry data and competitor performance metrics.

Titan Laboratories Private Limited's key differentiators include its specialization in finished pharmaceutical formulations across multiple therapeutic categories, with a significant concentration in Antiviral & HIV Medications, Advanced Antibiotics, and Advanced Oncology. The company's export data highlights a strong portfolio concentration, with the top five products accounting for 95.8% of the export value. This focus allows the company to leverage expertise in specific therapeutic areas, potentially enhancing product quality and market positioning.

Titan Laboratories Private Limited's current strategic direction appears to be centered on exporting finished pharmaceutical formulations to regulated markets, with a notable emphasis on Antiviral & HIV Medications, Advanced Antibiotics, and Advanced Oncology. The company's export data indicates a strong portfolio concentration in these areas. Future strategic directions may involve seeking certifications such as WHO prequalification and EU GMP to facilitate access to emerging markets and diversify its geographic footprint.

Titan Laboratories Private Limited demonstrates a consistent export volume, with 77 shipments across six products in five therapeutic categories, totaling $2.5 million USD. The top five products account for 95.8% of the export value, indicating a focused product strategy. While specific reliability indicators are not publicly disclosed, the company's sustained export activities suggest a stable and reliable supply chain.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards. This can be verified by checking the WHO's official prequalification list or by requesting certification details from the company.

• EU GMP Certification: Verify that the company holds European Union Good Manufacturing Practice certification. This information is typically available through the European Medicines Agency (EMA) or by contacting the company directly.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications related to quality management systems. These can be verified by requesting certification details from the company or by checking ISO's official database.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm that the company's products are approved by relevant regulatory authorities in the target market.

• Assess Manufacturing Facilities: Evaluate the company's manufacturing facilities for compliance with international quality standards.

• Review Financial Stability: Analyze the company's financial statements to assess its financial health and stability.

• Check for Legal Compliance: Ensure that the company complies with all applicable laws and regulations in its operating regions.

• Evaluate Supply Chain Reliability: Assess the reliability and consistency of the company's supply chain to ensure timely delivery of products.

Red flags to watch for include a lack of transparency in regulatory approvals, absence of quality certifications, financial instability, and a history of legal or compliance issues. Recommended pre-order checks involve requesting detailed product information, verifying certifications, and conducting site visits to manufacturing facilities if possible.